N/A N=60 A New Approach for Controlling Hemostasis During Canal Treatment
Blood Contamination of Root Canal During Endodontic Therapy
Primary: Change From Baseline in Root Canal Bleeding — 3.40; 3.73; 0.26; 3.03 millimeters — p=<.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=295 Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery
Venous Thromboembolism · Deep Venous Thrombosis · Pulmonary Embolus
Primary: Avoidance of Under-anticoagulation (Peak aFXa <0.2 IU/mL) — 76.6; 79.9 percentage of participants
Phase 4 N=98 Use of Tranexamic Acid in Reduction Mammoplasty
Hematoma Postoperative · Venous Thromboembolism
Primary: Number of Breasts With Development of Hematoma — 2; 1 breasts
Phase 3 N=57 Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures
Blood Coagulation Disorders · Hemorrhage
Primary: Change in Hemoglobin Level — -0.6; -0.4 g/dL
N/A N=111 Unipolar vs. Bipolar Hemostasis in Total Knee Arthroplasty: A Prospective Randomized Trial
Knee Arthroplasty
Primary: Drain Output. — 776; 778 mL
Phase 3 N=66 Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies
Lung Transplant; Complications, Mechanical · Lung Transplant; Complications · Bleeding
Primary: Intra-procedural Hemorrhage Grading by the Performing Bronchoscopist — 4; 13; 11; 24 Procedures
N/A N=26 Management of Persistent Epistaxis Using Floseal Hemostatic Matrix
Epistaxis
Primary: Number of Participants With Initial Hemostasis — 10; 11 Participants — p=1.000
Phase 4 N=196 The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery
Blood Loss
Primary: Change in Hemoglobin on Day 0 Compared to Preoperatively — -1.277; -1.241 g/dL
Phase 4 N=98 Clopidogrel Monotherapy in Patients With High Bleeding Risk
Bleeding Complications
Primary: Ischemic Risk Post-PCI in High Bleed Risk Patients With Genotype-guided Single Antiplatelet Therapy — 0; 1 Participants
Phase 3 N=52 Use of a Novel Fibrin Sealant in Total Knee Arthroplasty
Osteoarthritis · Intraoperative Bleeding
Primary: Primary--Percent Change of Pre- to Post-Operative Hemoglobin — 20.1; 22.5 Percent Change — p=0.2
Phase 3 N=44 Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery
Coronary Artery Disease
Primary: Total Volume of Blood Loss From Mediastinal Chest Tubes at Time of Removal (Assuming the Total Volume of Loss is Blood). — 632; 789 mL — p=0.0493
Phase 4 N=40 Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery
Chronic Sinusitis · Nasal Obstruction · Turbinate; Hypertrophy Mucous Membrane
Primary: Bleeding VAS - POD1 — 5.03; 4.82 score on a scale — p=0.8
Phase 4 N=100 Prospective Evaluation of Vitagel for Reduction in Blood Loss and Pain Following Unilateral Total Knee Arthroplasty
Arthritis
Primary: Number of Patients Managed With Blood Transfusion — 0; 5 participants
Phase 4 N=20 Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
Hypofibrinogenemia · Bleeding
Primary: Total Number of RBCs Used Over Admission — 5.8; 6.7 RBC Units
N/A N=200 Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage
Postpartum Hemorrhage · Uterine Atony
Primary: Blood Loss — 616; 418; 141; 106 cc
N/A N=103 SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects
Hemorrhage
Primary: Haemostatic Success at 5 Minutes — 90 Participants
Phase 4 N=200 The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery
Osteoarthritis
Primary: Change in Hemoglobin on Day 0 Compared to Preoperatively — -1.548; -1.458 g/dL
N/A N=62 Phlebotomy to Prevent Blood Loss in Major Hepatic Resections
Liver Neoplasms · Hepatectomy
Primary: Total Intraoperative Blood Loss, by Measurement of Change in Hemoglobin Levels — 862; 872; 761; 872 mL
Phase 3 N=721 A Study of Fibrocaps™ in Surgical Bleeding
Mild or Moderate Surgical Bleeding
Primary: Time to Hemostasis (TTH) for Participants Receiving Spinal Surgery — 1.0; 2.5 minutes — p=< 0.0001
N/A N=109 Comparison of Percutaneous Closure to Manual Compression for Hemostasis
Atrial Fibrillation
Primary: Time to Hemostasis — 4.5; 10.7 seconds
N/A N=20 Floseal Treatment for Posterior Epistaxis Study
Epistaxis
Primary: Effectiveness of Floseal for the Treatment of Posterior Epistaxis. — 20 participants
N/A N=192 Impact of Fluid Restriction Policy in Reducing the Use of Red Cells in Cardiac Surgery
Coronary Artery Disease · Coronary Artery Bypass · Erythrocyte Transfusion
Primary: Mean Number of Packed Red Cells Units Transfused During Hospital Stay — 1.13; 1.91 packed red cells units — p=<0.05
N/A N=100 The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass
Blood Coagulation Disorders
Primary: Amount of Chest Catheter Drainage 24 Hours Postoperatively — 766; 626 mL
N/A N=15 A New Approach for Controlling Hemostasis During Canal Treatment: a Pilot Study
Blood Contamination of Root Canal During Endodontic Therapy
Primary: Change From Baseline in Root Canal Bleeding Score — 2.33; 0.13 score on a scale — p=<.0001
Phase 2 N=51 Heart and Hands Study II: A Retrospective Data Collection & Analysis Project
Thrombosis
Primary: Incidence of Arterial Bleeding — 1 Participants
Phase 2 N=18 Evaluation of Blood as a Submucosal Cushion During Endoscopic Polypectomy and Mucosal Resection
Large Polyps in the Gastrointestinal Tract
Primary: Duration of the Submucosal Cushion
Phase 3 N=40 Blood Loss Reduction After Total Knee Arthroplasty. Comparison Topical Tranexamic Acid vs Platelet Rich Plasma
Osteoarthritis
Primary: Therapeutic Effect on Hemoglobin Level — 13.6; 13.6; 10.3; 9.9 g/dL
N/A N=70 Femoral Vein Hemostasis After Ablation for Atrial Fibrillation With Manual Pressure Versus a Figure of 8 Suture
Atrial Fibrillation
Primary: Time Required to Achieve Hemostasis — 0; 15 minutes
Phase 3 N=110 Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery
Post Partum Hemorrhage · Fibrinolysis; Hemorrhage · Blood Loss
Primary: Blood Volume Loss — 2274; 2407 milliliters
Phase 2 N=100 The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery
Hemorrhage
Primary: The Amount of Hemorrhage During Cesarean Delivery and Within 2 Hours Afterward — 260; 380 ml